Microvascular

Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study

Top

Nielsen SF, Nordestgaard BG. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study. Lancet Diabetes Endocrinol. 2014. [ePub ahead of print] doi: 10.1016/S2213-8587(14)70173-1.

Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy.

Top

Exclusive! Expert commentary webcast from Vivian Fonseca, MD, on this post-hoc analysis of ADVANCE. Morton J, Zoungas S, Li Q, et al; on behalf of the ADVANCE Collaborative Group. Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy. Diabetes Care. 2012;35:2201-2206. Macro- and microvascular complications remain significant concerns in the treatment of patients with type 2 diabetes.

Should the Hemoglobin A1c Diagnostic Cutoff Differ Between Blacks and Whites?: A Cross-sectional Study

Top

Tsugawa Y, Mukamal KJ, Davis RB, Taylor WC, Wee CC. Should the Hemoglobin A1c Diagnostic Cutoff Differ Between Blacks and Whites? A Cross sectional Study. Ann Intern Med. 2012;157(3):153-159. Hemoglobin A1c (HbA1c) levels are known to be consistently higher in black persons than in white persons at any given glycemic level. Whether the optimal diagnostic threshold of HbA1c should differ between blacks and whites is unclear.

Assessing Vascular Disease Risk Associated with Medication-Related Hypoglycemia

Top

Exclusive! Expert video from Burton E. Sobel, MD, on the debate over intensive vs somewhat less intensive glycemic control in the context of this study. Zhao Y, Campbell CR, Fonseca V, Shi L. Assessing Vascular Disease Risk Associated with Medication-Related Hypoglycemia. Diabetes Care. 2012;35(5):1126-1132. Zhao and colleagues examined the impact of hypoglycemia associated with antihyperglycemic medications on vascular risk among veterans with type 2 diabetes in a retrospective cohort study.

ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia

Top

Exclusive! Expert commentary from Silvio E. Inzucchi, MD, on the ORIGIN glargine trial. ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia. N Engl J Med. 2012;367(4):319-328. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes

ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia

Top

Exclusive! Video commentary from Vivian A. Fonseca, MD. ORIGIN Trial Investigators, Bosch J, Gerstein HC, et al. ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia. N Engl J Med. 2012;367(4):309-318. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes.

Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis

Top

Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR. Role of intensive glucose control in development of renal end points in type 2 diabetes: systematic review and meta-analysis. Arch Intern Med. 2012;172(10:761-769

Variation of fasting plasma glucose: a predictor of mortality in patients with type 2 diabetes

Top

Variation of fasting plasma glucose a predictor of mortality in patients with type 2 diabetes Lin CC, Li CI, Yang SY, Liu CS, Chen CC, Fuh MM, Chen W, Li TC. Am J Med. 2012 125(4) 416.e9 18.  The aim of this study was to examine whether time-dependent annual fasting plasma glucose (FPG) variation, as represented by coefficient of variation (CV), can predict mortality in subsequent all-cause, expanded, and nonexpanded cardiovascular disease-related mortality independent of mean FPG, renal function, mean hemoglobin A(1)C (HbA(1C)), HbA(1C) variation, and other risk factors in patients with type 2 diabetes.

Treatment of Type 2 Diabetes in the Elderly

Top

Treatment of Type 2 Diabetes in the Elderly Munshi MN, Maguchi M, Segal AR. Curr Diab Rep. 2012 Apr 10. Epub ahead of print   As the number of older adults increases in the United States and worldwide, management of patients with multiple coexisting chronic diseases has become a critical component in health care.

Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the ACCORD experience

Top

Bonds DE, Craven TE, Buse J, Crouse JR, Cuddihy R, Elam M, Ginsberg HN, Kirchner K, Marcovina S, Mychaleckyj JC, O'Connor PJ, Sperl-Hillen JA. Fenofibrate associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia. 2012 Mar 27. Epub ahead of print. Fenofibrate has been noted to cause an elevation in serum creatinine in some individuals.

1 2 3 4 5 6 7 8 9 10  ... Next